BriaCell Therapeutics Corp (BCTX)

The past six months have seen significant volatility in BriaCell's stock. In January 2026, the stock surged nearly 43% after the company reported a complete resolution of lung metastasis in a patient treated with its Bria-OTS immunotherapy, but then dropped after announcing a $30 million public offering priced at $5.59 per unit. The closing of this US$30 million public offering was also announced in January 2026. Over a broader period, between February 6, 2025, and February 5, 2026, the share price experienced a substantial decline of 89.70%. In September 2024, the company announced the pricing of an $8.5 million offering. A proposed effective date for a share consolidation was announced in August 2025.

Information regarding specific demand seasonality for BriaCell Therapeutics Corp.'s products and services is not available. Demand for its products is primarily driven by the progress of clinical trials, regulatory approvals, and the prevalence of the targeted diseases, rather than typical seasonal consumer patterns.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing innovative immunotherapies to transform cancer care, primarily targeting breast cancer. Its major product candidates include Bria-IMT, a patented, off-the-shelf, cell-based targeted immunotherapy currently in a pivotal Phase 3 study for metastatic breast cancer, often in combination with an immune checkpoint inhibitor like Retifanlimab. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which aim to provide matched treatment to a high percentage of patients for various cancers, including breast and prostate cancer. Additionally, BriaCell is developing a soluble CD80 protein therapeutic that acts as both an immune system stimulator and an immune checkpoint inhibitor.

BriaCell Therapeutics Corp. is headquartered in West Vancouver, British Columbia, Canada. The company's shares are listed on the Nasdaq Capital Market (NasdaqCM) in the US, the Toronto Stock Exchange (TSX) in Canada, and Deutsche Boerse AG (DB) in Germany.

BriaCell's brand reputation has been influenced by positive clinical and corporate developments, including positive patient images, extended survival in Phase 2 metastatic breast cancer patients, and a Phase 3 trial feature in Nature Medicine. The company presented data at SABCS® 2025, announced a collaboration with Receptor.AI, received a positive DSMB recommendation, and announced a collaboration with MSK Accelerator. BriaCell was awarded a $2 Million NCI Grant and received FDA fast-track designation for Bria-IMT in combination with retifanlimab. Despite these positive developments, WallStreetZen has given BCTX a "Strong Sell" Zen Rating (F) and an Industry Rating of F, while MarketBeat's MarketRank™ scored BriaCell higher than 74% of evaluated companies.

Major institutional shareholders include Citadel Advisors Llc, Flagship Harbor Advisors, Llc, Federation des caisses Desjardins du Quebec, UBS Group AG, Morgan Stanley, Royal Bank Of Canada, Allworth Financial LP, Group One Trading, L.p., TD Waterhouse Canada Inc., and FNY Investment Advisers, LLC. Insiders hold 5.73% of the company's stock.